Home › Research › Drug development
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?
Beveridge J, Kaniecki E, Naidu A, Silverglate BD, Grossberg G.. Expert opinion on emerging drugs, 2024-01-12
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Introduction Monoclonal antibodies targeting amyloid-β are the first disease-modifying treatments for Alzheimer disease to have received FDA-approval. There are three different drugs approved or pending FDA-approval: aducanumab, lecanemab, and donanemab. These three drugs are each in different stages of regulatory approval by the FDA.
What this study adds
Evidence grade: Low
This is a narrative review. This paper reviews three monoclonal antibodies targeting amyloid-β—aducanumab, lecanemab and donanemab—which are the first disease-modifying treatments for Alzheimer disease to receive FDA approval or be pending it. It discusses their clinical efficacy, dosing, side effects and practical issues with using them as common treatments to slow decline.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Beveridge, J., Kaniecki, E., Naidu, A., Silverglate, B. D., & Grossberg, G. (2024). How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease? Expert opinion on emerging drugs. https://doi.org/10.1080/14728214.2024.2304059
Vancouver
Beveridge J, Kaniecki E, Naidu A, Silverglate BD, Grossberg G. How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease? Expert opinion on emerging drugs. 2024. doi:10.1080/14728214.2024.2304059. PMID: 38193477.
BibTeX
@article{beveridge2024-38193477,
author = {Beveridge, J. and Kaniecki, E. and Naidu, A. and Silverglate, B. D. and Grossberg, G.},
title = {{How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?}},
journal = {Expert opinion on emerging drugs},
year = {2024},
doi = {10.1080/14728214.2024.2304059},
pmid = {38193477},
url = {https://doi.org/10.1080/14728214.2024.2304059}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- There are three different drugs approved or pending FDA-approval: aducanumab, lecanemab, and donanemab.
- These three drugs are each in different stages of regulatory approval by the FDA.
- Areas covered We discuss the development of these drugs, the data regarding their clinical efficacy, their dosing regimens, and side effects.
- In addition, we examine pragmatic issues with their potential implementation as common treatments to slow the rate of decline in Alzheimer disease, and what unanswered questions remain regarding this new class of drugs.
Why it matters
This paper reviews three monoclonal antibodies targeting amyloid-β—aducanumab, lecanemab and donanemab—which are the first disease-modifying treatments for Alzheimer disease to receive FDA approval or be pending it. It discusses their clinical efficacy, dosing, side effects and practical issues with using them as common treatments to slow decline.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 34/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomized / blinded because the record does not state it.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Expert opinion on emerging drugs) |
| Journal's citation record | 0 / 4 | Expert Opinion on Emerging Drugs: journal h-index 63 (OpenAlex, 2026-10-29) |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | 2 / 7 | Cited 10 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 2.5 citations a year over 4 year(s) since 2024 |
| Impact for its field and year | 2 / 6 | Cited 2.4× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 1 / 6 | Cited by 1 other studies in this library |
| Still being cited | 1 / 4 | Cited 10 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 3 / 4 | Last-listed author George Thomas Grossberg: h-index 58 (OpenAlex, whole career) |
| Institution's track record | 0 / 3 | Saint Louis University: institution h-index 567 (OpenAlex) |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 1 institution(s) in 1 country — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 38193477) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 34 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 13.
Later studies that cite this one
1 study in the alzhub library lists this one in its references.
Related studies in Drug development from nearby years
Also in Drug development
124 studies in the library are filed under Drug development with no topic tag they share with another; these are this study's neighbours in a fixed tour of them. The Drug development hub.